LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...
Over the past decade, AstraZenecaAZN has built a broad oncology franchise spanning multiple cancer types, including lung, ...
Pfizer PFE and AstraZeneca AZN are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company ...
U.S. District Judge Matthew Kennelly determined that, opens new tab the two patents Pfizer accused AstraZeneca of infringing with its blockbuster lung-cancer drug Tagrisso were invalid. Sign up here.
Pfizer (NYSE:PFE) reported breakthrough Phase 3 results for its BRAFTOVI combination in first-line metastatic colorectal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results